All In Biotech

Drug Trial Radar · NCT05610085

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

A Phase IIb Dose Escalation Study of Levetiracetam for the Treatment of Neonatal Seizures

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

133

Planned (sponsor's estimate)

Start

Mar 24, 2023

Primary completion

Jul 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
University of California, San DiegoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Minnesota; Rady Children's Hospital, San Diego; Auckland City Hospital; University of Auckland, New Zealand; Middlemore Hospital, New Zealand; Waikato Hospital
First posted
Nov 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 1 month
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation, preliminary safety and efficacy study. There will be a randomized control treatment component. Infants recognized as having neonatal seizures or as being at risk of developing seizures will be recruited and started on continuous video EEG monitoring (CEEG). Eligibility will be confirmed and consent will be obtained. In the first 2 phases of the study, neurologists will identify neonates with mild-moderate seizure burden (less than 8 minutes cumulative seizure activity per hour), appropriate for study with LEV, and exclude patients with higher seizure burden where treatment with PHB is more appropriate. Phase 3 of the dose escalation will only proceed if additional efficacy of LEV has been demonstrated in phases 1 and 2. In Phase 3 we will recruit neonates with seizures of greater severity up to 20 minute seizure burden/hour. This will make the final results of study more generalizable. If seizures are confirmed, enrolled subjects will receive 60mg/kg of LEV. Subjects whose seizures persist or recur 15 minutes after the first infusion is complete, subjects will then be randomized in the dose escalation study. Patients in the dose escalation study will be randomly assigned to receive either higher dose LEV or treatment with the control drug PHB in a 3:1 allocation ratio, stratified by site. Funding Source- FDA OOPD

Conditions

  • Neonatal Seizure
  • Neonatal Encephalopathy
  • Hypoxic-Ischemic Encephalopathy
  • Seizure Newborn

Interventions

  • Levetiracetam InjectionDrug

    Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital

  • Phenobarbital Sodium InjectionDrug

    Standard of care for neonatal seizures

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is the maximum safe and tolerated dose of LevetiracetamTime frame: 4 years

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, San Diego

    San Diego, California · Completed

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Auckland City Hospital

    Auckland, Auckland, New Zealand · Recruiting

  • Middlemore Hospital

    Auckland, Auckland, New Zealand · Recruiting

  • Health New Zealand, Te Whatu Ora - Waikato Hospital

    Hamilton, Waikato Region, New Zealand · Recruiting

  • Capital and Coast District Health Board, Te Whatu Ora, Health New Zealand

    Wellington, Wellington Region, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.